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Exploring the potential of gold(III) cyclometallated
compounds as cytotoxic agents: variations on the
C^N theme†
B. Bertrand,a,b S. Spreckelmeyer,a,c E. Bodio,b F. Cocco,d M. Picquet,b P. Richard,b
P. Le Gendre,b C. Orvig,c M. A. Cinellu*d and A. Casini*a
A series of novel (C^N) cyclometallated Au(III) complexes of general formula [Au(pyb-H)L1L2]n+ (pyb-H =
C^N cyclometallated 2-benzylpyridine, L1 and L2 being chlorido, phosphane or glucosethiolato ligands,
n = 0 or 1) have been synthesized and fully characterized using diﬀerent techniques, including NMR,
IR and far-IR, mass spectrometry, as well as elemental analysis. The crystal structure of one compound
has been solved using X-ray diﬀraction methods. All compounds were tested in vitro in ﬁve human cancer
cell lines including the lung, breast, colon and ovarian cancer cells. For comparison purposes, all com-
pounds were also tested in a model of healthy human cells from the embryonic kidney. Notably, all new
compounds were more toxic than their cyclometallated precursor bearing two chlorido ligands, and the
derivative bearing one phosphane ligand presented the most promising toxicity proﬁle in our in vitro
screening, displaying a p53 dependent activity in colorectal cancer HCT116 cells. Finally, for the ﬁrst time
C^N cyclometallated gold(III) complexes were shown to be potent inhibitors of the zinc ﬁnger protein
PARP-1, involved in the mechanism of cisplatin resistance.
Introduction
Metallodrugs play an important role in the treatment of
several diseases. Among them, cisplatin [cis-diamminedichlor-
ido platinum(II)], discovered accidentally,1 is widely used in
chemotherapy due to its strong eﬀects against ovarian, testicu-
lar and lung cancer. Unfortunately, anticancer therapy with
cisplatin has a range of limitations, including resistance,
limited spectrum of action and severe side eﬀects, including
nephrotoxicity. For this reason, since cisplatin’s discovery,
numerous Pt-based anticancer agents have been developed to
minimize such harmful side eﬀects.2 However, to date, only
two additional Pt(II) compounds have achieved international
marketing approval, carboplatin and oxaliplatin, although not
being deprived of toxic eﬀects.3 In the eﬀort to develop
improved anticancer metallodrugs, several other metal com-
plexes have been explored in vitro and in vivo, including com-
pounds of Fe, Ru, Ti and Au.4–6
On the basis of these chemical considerations, the peculiar
properties of gold have been exploited for several applications.
To date, many complexes containing Au in +1 and +3 oxidation
states have shown therapeutic properties against cancer or
inflammatory diseases. When exploiting the reactivity of gold
derivatives against cells, one should bear in mind also the
noble metal characteristics. Thus, the stabilization of the oxi-
dation states +1 and +3 is of paramount importance to observe
any kind of biological activity. Otherwise, the metal center can
ultimately undergo reduction process, thus leading to the for-
mation of Au(0).7
In this context, the development of anticancer gold
organometallics of various families has identified promising
candidates with anticancer properties, including Au(I) alkynyl
complexes, Au(I/III) N-heterocyclic carbene (NHC) complexes
and Au(III) cyclometallated complexes.8–12 The advantage of
NHC and cyclometallated organometallic gold compounds
is their relative stability with respect to other classical coordi-
nation complexes. There is evidence that Au compounds
preferentially target proteins in biological environments, such
as the Se-enzyme thioredoxin reductase (TrxR),13–16 Zn finger
enzymes,17,18 as well as the membrane water and glycerol
channel aquaglyceroporins.19–21
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Notably, increasing interest is focused on the family of
cyclometallated gold(III) complexes, in which the Au3+ ions are
highly stabilized under physiological conditions. Recently, we
reviewed a variety of cyclometallated gold(III) complexes of
diﬀerent scaﬀolds, namely (C^N)Au, (C^N^N)Au, and (C^N^C)-
Au complexes.8 For example, Fricker and coworkers reported
the synthesis and biological activity of square-planar six-mem-
bered cycloaurated Au(III) compounds with a pyridinyl–phenyl
linked backbone and two monodentate or one bidentate
leaving group(s), which were able to inhibit the cysteine pro-
teases cathepsins B and K in vitro.22 Structure/activity relation-
ships were investigated by modifications to the pyridinyl–phenyl
backbone, and leaving groups, demonstrating optimal activity
with substitution at the 6 position of the pyridine ring. In this
study, the importance of the leaving groups was also high-
lighted.22 Moreover, one of the derivatives containing thiosali-
cylate, as one of the ligands bound to the (C^N)Au scaﬀold, was
tested in vivo against the HT29 human colon tumor xenograft
model, where a modest decrease in tumor growth was observed
compared to the untreated control tumor.22
Taking into account these promising studies, we report
here the synthesis and characterization of a new series of four
gold(III) cyclometallated compounds of the general formula
[Au(pyb-H)L1L2]n+ (pyb-H = C^N cyclometallated 2-benzylpyri-
dine, L1 and L2 being 1,3,5-triazaphosphaadamantane (PTA),
thio-β-D-glucose tetraacetate (GluS−) or chlorido ligands; n = 0, 1).
Notably, the PTA ligand was chosen for its good water solubi-
lity, while the GluS− ligand was selected with the aim of facili-
tating uptake into cancer cells modulating the lipophilic/
hydrophilic character, as well as via possible interaction with
GLUT1 transporters.23 Moreover, binding of Au(III) to thiolate
should prevent ligand exchange reactions with biological
nucleophiles leading to inactivation of the compound. The
four new gold(III) compounds were obtained in good yields
and fully characterized by 1H-NMR, 13C-NMR, 31P-NMR
and far-IR, as well as X-ray crystallography for compound
[Au(pyb-H)(PTA)Cl][PF6] (2-PF6). All complexes were tested vs. a
panel of human cancer cell lines, as well as in non-tumori-
genic human embryonic kidney cells HEK-293 T in vitro. Since
Pt drugs have been known to elicit apoptosis in certain cell
lines via a p53-dependent pathway,24 the human colorectal car-
cinoma HCT116 p53+/+ cells overexpressing p53, and HCT116
p53−/− cells knock-out for this gene were selected to compare
the antiproliferative eﬀects of the Au complexes with cisplatin.
Finally, the selected compounds were tested as inhibitors of
the enzyme poly(adenosine diphosphate [ADP-ribose]) poly-
merase 1 (PARP-1). It is worth mentioning that PARPs are Zn
finger proteins playing a key role in DNA repair by detecting
DNA strand breaks and catalyzing poly(ADP-ribosylation).25,26
Specifically, PARP-1 is involved in the cisplatin resistance
mechanism in cancer cells.24
Results and discussion
Synthesis and structural characterization
The (C^N) cyclometallated precursor [Au(pyb-H)Cl2] (1) (py
b-
H = C^N cyclometallated 2-benzylpyridine) was synthesized as
described by Cinellu et al. by the reaction of sodium tetra-
chloridoaurate with 2-benzylpyridine (pyb) in refluxing MeCN/
H2O overnight.
27 As previously reported, replacement of one
chlorido ligand by triphenylphosphine can be achieved by
reacting 1 with one equivalent of PPh3 in the presence of
excess KPF6 or NaBF4.
27 Following this method, we prepared
the new phosphane derivative [Au(pyb-H)(PTA)Cl][PF6] (2-PF6)
containing 1,3,5-triazaphosphaadamantane (PTA), which is
not toxic to cancer cells and is known in general to improve
water solubility. Thus, by reacting 1 with one equivalent of PTA
in the presence of KPF6 for 1.5 hours at room temperature, we
obtained 2-PF6 in a very good yield (Scheme 1). Complexation
of the phosphane ligand as well as the isomeric purity of 2-PF6
were assessed by 31P NMR showing the PF6
− anion heptuplet
Scheme 1 Synthesis of novel (C^N)gold(III) cyclometallated compounds.
Paper Dalton Transactions
11912 | Dalton Trans., 2015, 44, 11911–11918 This journal is © The Royal Society of Chemistry 2015
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
6 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
8/
04
/2
01
6 
15
:2
2:
40
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
signal centred at −144.4 ppm and a singlet of the coordinated
phosphorous at −14.2 ppm, downfield shifted by 86 ppm with
respect to the free phosphane ligand.
Of the two possible geometrical isomers, trans-P–Au–N or
trans-P–Au–C, the IR and 1H NMR spectra, taken together,
support a trans-P–Au–N arrangement. Indeed, in the IR spec-
trum the Au–Cl stretching vibration is observed at values con-
sistent with a chlorine trans to a carbon atom (see the
Experimental section) and in the 1H NMR spectrum the H6
proton (for numbering scheme, see Scheme 2) of the pyridine
is strongly deshielded with respect to the free ligand (Δδ =
0.44 ppm), as usually observed in related complexes and
reflects the through-space influence of the adjacent chloride
ligand.27
X-ray-quality crystals of 2-PF6 were obtained by slow
diﬀusion of diethyl ether into an acetone solution and the
structure in the solid state was solved by X-ray diﬀraction ana-
lysis. The solid state molecular structure of the cation is
depicted in Fig. 1 with principal bond lengths and angles
reported in Table 1; the corresponding bond parameters of the
analogous triphenylphosphine complex [Au(pyb-H)(PPh3)Cl]-
[BF4]
28 (5-BF4) are also reported for comparison. The com-
pound crystallizes in the P21/n monoclinic space group and
the asymmetric unit contains two independent cations, two
independent PF6
− anions and one acetone molecule (Fig. S1 in
the ESI†). The conformations of the two cations are similar
and simply diﬀer by a rotation of the PTA groups by about 19°,
thus for simplicity reasons, the following description will only
be with regard to one of these cations (depicted in Fig. 1). The
gold atom displays an almost regular square-planar coordi-
nation, with a slight distortion in the N–Au–C angle: 87.39(7)°
(Fig. 1). The bite angle of the six-membered cyclometallated
ring, the bond lengths and angles involving the gold atom are
comparable to those observed in 5-BF4 by Fuchita (Table 1);
28
small diﬀerences – e.g. in the Au–N bond distance – may be
attributed to the diﬀerent electronic and steric properties of
the two phosphane ligands. Moreover, the six-membered
metallacycle is in a boat-like conformation (Fig. 1B) with
atoms C1, C6, C8 and N1 essentially coplanar within the esti-
mated standard deviation. This best plane forms dihedral
angles with planes C6–C7–C8 and N1–Au1–C1 of 48.75(16) and
39.34(9)°, which is in line with previous observations made by
Fuchita et al. for 5-BF4.
28 Notably, the PTA ligand is trans to
the nitrogen of the cyclometallated ligand, as previously
suggested by the FIR and 1H NMR spectra.
Complex 1 was also treated with one or two equivalents of
thio-β-D-glucose tetraacetate (GluSH) and sodium carbonate in
dichloromethane for 1.5 hours to obtain compound 3, or over-
night to obtain compound 4 in good yields. The non-planarity
and the conformational stability of the cyclometallated Au(III)
scaﬀold give rise to a planar chirality which upon coordination
with optically pure tetraacetylated β-D-glucosethiolate leads to
the formation of a mixture of diastereoisomers. In both the 1H
and 13C NMR spectra, 3 presents doubled signals in a 50/50
ratio for protons and carbons close to the metal centre due to
the equimolar presence of the two possible diastereoisomers.
The largest split is observed for H6′ with a diﬀerence of
0.25 ppm between the two diastereoisomers, while the signals
of H6 are separated by only 0.03 ppm, thus suggesting close
proximity of H6′ to the chiral centres. The 1H NMR spectrum of
4 was quite complex, showing two signals for each proton of
the cyclometallated ligand in a ratio of 1/0.3. These signals cor-
respond neither to the precursor 1 nor to the mono-sugar 3.
However, the structure of the compound was further assessed
by the association of the ESI-MS spectra showing the peak of
adduct [4 + Na]+ and the elemental analysis corresponding to
4·H2O.
In the absence of a crystal structure determination for
complex 3, to discriminate between the two possible isomers,
i.e. thio-glucose in trans position to the carbon or to the nitro-
gen atom (Fig. S2†), its far-IR (FIR) spectrum was compared
to those of the other complexes, whose structures were known
Scheme 2 1H and 13C labelling used for the attribution of the NMR
signals of the cyclometallated ligand.
Fig. 1 ORTEP view of the cation in complex 2-PF6; top (A) and side (B)
views.
Table 1 Selected bond distances (Å) and angles (°) with estimated stan-
dard deviations in parentheses for compound 2-PF6 and 5-BF4
28
Distances (Å) and
angles(°)
2-PF6 (for both
independent molecules) 5-BF4
Au–C 2.040(2) 2.042(2) 2.03(1)
Au–N 2.0961(18) 2.0998(18) 2.079(10)
Au–P 2.2709(6) 2.2840(6) 2.311(3)
Au–Cl 2.3696(5) 2.3612(5) 2.362(3)
C–Au–N 87.39(7) 87.26(8) 85.8(4)
C–Au–P 93.44(6) 91.92(6) 94.8(3)
C–Au–Cl 178.35(6) 177.56(6) 175.2(3)
N–Au–P 175.43(5) 177.43(5) 176.4(3)
N–Au–Cl 91.25(5) 90.31(5) 89.4(3)
P–Au–Cl 87.985(19) 90.512(19) 89.9(1)
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(2-PF6 and 5-BF4) or unambiguous (1 and 4). Indeed, in this
range of energy we can observe the stretching bands of Au–Cl
and Au–S bonds. The main FIR bands are shown in Table S2
in the ESI.†
The dichlorido complex 1 displays a medium band at
358 cm−1 and a strong one at 287 cm−1, corresponding to the
stretching of the Au–Cl bonds in trans position to the nitrogen
and carbon atoms, respectively. In the case of 2-PF6, the FIR
spectrum shows an intense band at 310 cm−1 close to the
value (305 cm−1) observed for the analogous complex with
PPh3, consistent with a chlorine trans to the carbon atom of
the phenyl substituent.
Compound 3 presents two bands: a broad one at 372 cm−1
corresponding to the Au–S bond trans to a nitrogen atom, and
a strong one at 295 cm−1 corresponding to the Au–Cl bond
in trans position to the carbon atom. As expected, the FIR
spectra of 4 did not show any Au–Cl stretching band, but a
broad double band with peaks at 375 and 369 cm−1, consist-
ent, respectively, with a sulfur trans to a nitrogen and to a
carbon atom.
Antiproliferative activity
Compounds 1, 2-PF6, 3 and 4 were screened for their antiproli-
ferative properties in vitro in a panel of human cancer cell
lines including ovarian adenocarcinoma (A2780), mammary
carcinoma (MCF-7), lung carcinoma (A549) and colon carci-
noma overexpressing p53 (HCT116 p53+/+) or p53 knock-out
(HCT116 p53−/−), as well as on healthy human embryonic
kidney cells (HEK-293T). The IC50 was determined after
72 hours of incubation with diﬀerent concentrations of com-
pounds using the classical MTT test. The results are summar-
ized in Table 2.
In general, the new cyclometallated complexes 2-PF6, 3 and
4 were more toxic than their precursor 1, containing two chlor-
ido ligands, in all cell lines with the exception of the A549 cell
line in which most of the gold complexes appeared to be
poorly toxic. The phosphane-containing complex 2-PF6 pre-
sents the most interesting toxicity profile, comparable to that
of cisplatin in A2780 cells (IC50 = 2.7 ± 0.2 and 1.9 ± 0.6 μM,
respectively). Furthermore, complex 2-PF6 is twice as toxic as
cisplatin against HCT116+/+ cells (IC50 = 2.1 ± 0.7 and 5.3 ±
0.2 μM) and poorly eﬀective on the HCT116 p53−/− (IC50 =
14.0 ± 1.1 μM). The latter result suggests similar dependence
on p53 pathways for compound 2-PF6 as for cisplatin. In terms
of selectivity, 2-PF6 is also ca. 3-fold less toxic on the HEK-293T
cells compared to the HCT116 p53+/+. Compounds 3 and 4
showed overall moderate antiproliferative properties, and
their inactivity rules out the idea that the tetra-acetylated
β-D-glucose-1-thiolato ligand may enhance the uptake of the
compounds, for example through GLUT-1 transporters.
Indeed, our previously reported studies on Au(I) NHC com-
plexes with similar thio-sugar ligands also showed scarce cyto-
toxic eﬀects most likely due to poor gold uptake.29
PARP-1 inhibition
In order to further investigate the mechanism of action of our
organometallic compounds, and inspired by our recent results
that indicate that some cytotoxic gold(III) compounds are
eﬃcient inhibitors of the zinc-finger protein PARP-1,17 we
tested complexes 1 and 2-PF6 on the purified human enzyme
as described in the Experimental section. Remarkably, potent
PARP-1 inhibition was indeed observed with both compounds:
1 with IC50 = 1.30 ± 0.40 nM, and 2-PF6 with IC50 = 1.87 ± 0.20
nM, respectively. Notably, these values are in the same range
of those previously observed for Au(III) complexes with N-donor
ligands.17
Conclusions
The potential of organometallic compounds for biological
applications, including as anticancer agents, has been demon-
strated by numerous studies.30 Here, we report the synthesis
and characterization of a new series of (C^N) cyclometallated
gold(III) complexes bearing diﬀerent ancillary ligands selected
to confer diﬀerent reactivity and biological properties to the
resulting compounds, such as PTA for increased water-solubi-
lity, and thio-sugar moieties to influence uptake and reduce
exchange with biological nucleophiles. The X-ray structure of
compound 2-PF6 was solved and revealed the typical square-
planar geometry of the gold(III) cation, as well as the coordi-
nation of the phosphane ligand trans to the nitrogen. Com-
pound 1, which is the precursor of the series, was poorly
cytotoxic on all cell lines, while the phosphane-containing
compound 2-PF6 shows the most promising results against the
HCT116 cancer cell line overexpressing p53.
Table 2 Antiproliferative eﬀects of compounds 1–4 (IC50 values) compared to cisplatin in diﬀerent human cancer cell lines after 72 h of incubation
IC50
a (μM)
Comp. A2780 HCT116 p53+/+ HCT116 p53−/− MCF7 A549 HEK-293T
1 36.1 ± 7.8 25.5 ± 6.6 21.1 ± 3.1 25.5 ± 4.7 54.4 ± 0.3 21.0 ± 5.1
2-PF6 2.7 ± 0.2 2.1 ± 0.7 14.0 ± 1.1 15.6 ± 4.6 40.5 ± 5.0 7.1 ± 0.8
3 15.7 ± 7.4 9.7 ± 4.8 18.4 ± 1.1 19.7 ± 3.8 40.0 ± 0.7 11.7 ± 6.1
4 17.4 ± 4.5 10.5 ± 2.0 18.5 ± 0.6 15.1 ± 3.9 18.2 ± 1.2 12.9 ± 3.1
Cisplatin 1.9 ± 0.6 5.3 ± 0.2 22.9 ± 2.3 20.0 ± 3.0 12.06 ± 0.8 8.6 ± 1.3
a The reported values are the mean ± SD of at least three determinations.
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Interestingly, compounds 1 and 2-PF6 inhibited the zinc-
finger enzyme PARP-1 in nM concentrations, suggesting the
possible design of selective inhibitors and the use of organo-
metallic gold compounds in combination therapies with other
anticancer drugs. PARP inhibitors are currently highly investi-
gated for their selective cytotoxic properties and can be con-
sidered as DDR inhibitors,31 which can be used in
combination with classical DNA damaging agents for optimiz-
ing the therapeutic outcome.
Overall, our study shows the potential for improvement of
the biological properties of organometallic gold-based com-
pounds by tuning their coordination environment. Further
studies are ongoing to evaluate the mechanisms of transport
and possible targets for this new series of gold compounds,
including interactions with nucleic acids.
Experimental section
General remarks
All reactions were carried out under purified argon using the
Schlenk techniques. Solvents were dried and distilled under
argon before use. The precursor [Au(pyb-H)Cl2] was syn-
thesized according to a literature procedure.26 All other
reagents were commercially available and used as received. All
the physico-chemical analyses were performed at the “Plate-
forme d’Analyses Chimiques et de Synthèse Moléculaire de
l’Université de Bourgogne”. The identity and purity (≥95%) of
the complexes were unambiguously established using high-
resolution mass spectrometry and NMR. The exact mass of the
synthesized complexes was obtained on a Thermo LTQ Orbi-
trap XL. 1H- (300.13, 500.13 or 600.23 MHz), 13C- (125.77 or
150.90 MHz) and 31P- (121.49, 202.45 or 242.94 MHz) NMR
spectra were recorded on Bruker 300 Avance III, 500 Avance III
or 600 Avance II spectrometers, respectively. Chemical shifts
are quoted in ppm (δ) relative to TMS (1H and 13C) using the
residual protonated solvent (1H) or the deuterated solvent
(13C) as internal standards. 85% H3PO4 (
31P) was used as an
external standard. Infrared spectra were recorded on a Bruker
Vector 22 FT-IR spectrophotometer (Golden Gate ATR) and far
infrared spectra were recorded on a Bruker Vertex 70v FT-IR
spectrophotometer (Diamant A225 ATR). X-ray diﬀraction data
for 2 were collected on a Bruker Nonius Kappa CCD APEX II at
115 K.
Synthesis of cyclometallated gold(III) complexes based on
2-benzylpyridine ligand (pyb)
[Au(pyb-H′)Cl2] (1). A round-bottom flask was charged with
NaAuCl4·2H2O (1 eq., 1.19 g, 3.00 mmol) dissolved in distilled
water (60 mL). Benzylpyridine (1 eq., 0.482 mL, 3.00 mmol)
was added at room temperature and a yellow precipitate was
formed. The reaction mixture was refluxed overnight until the
yellow precipitate turned white. After filtration, the white solid
was washed with methanol, and re-crystallised from a dichlor-
omethane/Et2O mixture to give the pure product (912 mg, 70%
yield). 1H NMR (acetone-d6, 500.13 MHz, 298 K): 4.39 (d, 1H,
JAB = 15.6 Hz, CHAHB), 4.66 (d, 1H, JAB = 15.6 Hz, CHAHB), 7.18
(m, 1H, JH–H = 7.6 Hz, H
4′), 7.30 (m, 1H, JH–H = 7.6 Hz, H
5′),
7.28 (d, 1H, JH–H = 7.6 Hz, H
3′), 7.49 (d, 1H, JH–H = 8.0 Hz, H
6′),
7.74 (m, 1H, JH–H = 6.8 Hz, H
5), 8.05 (m, 1H, JH–H = 7.6 Hz, H
3),
8.31 (m, 1H, JH–H = 7.6 Hz, H
4), 9.30 (d, 1H, JH–H = 6.4 Hz, H
6).
Assignments based on 2D-COSY spectra. IR (νmax, cm
−1): 3050,
1609, 1564, 1482, 1435, 1024, 829, 747, 358, 287.
[Au(pyb-H)(PTA)Cl](PF6) (2-PF6). A round-bottom flask was
charged with 1 (1 eq., 50 mg, 0.115 mmol) and KPF6 (5 eq.,
106 mg, 0.573 mmol) in suspension in acetone (5 mL). PTA
(1 eq., 18 mg, 0.115 mmol) was added to the mixture at room
temperature leading to the solubilisation of the starting Au
complex. The reaction mixture was maintained at room temp-
erature for 1.5 h. After partial removal of the solvent, dichloro-
methane was added and the solution was filtered through
Celite® and the solvents evaporated to dryness. The pure
product was obtained after recrystallization from a dichloro-
methane/pentane mixture (80.3 mg, 98% yield). 1H NMR
(acetone-d6, 500.13 MHz, 298 K): 4.40 (d, 1H, JAB = 15.6 Hz,
CHAHB-py
b), 4.61 (2 d, 4H, JAB = 15.6 Hz, JAB = 13.2 Hz, CHAHB-
pyb, 3 N–CHAHB–N), 4.81 (d, 3H, JAB = 13.2 Hz, 3 N–CHAHB–N),
4.96 (d, 6H, 3JP–H = 3.6 Hz, N–CH2–P), 7.22 (m, 1H, JH–H =
7.4 Hz, 1.0 Hz, H5′), 7.32 (m, 1H, JH–H = 7.6 Hz, H
4′), 7.48 (dd,
1H, JH–H = 7.6 Hz, 1.0 Hz, H
3′), 7.77 (m, 1H, JH–H = 7.0 Hz, 1.0
Hz, H5), 7.86 (ddd, 1H, JH–H = 7.5 Hz, 1.0 Hz,
4JP–H = 3.5 Hz,
H6′), 8.02 (d, 1H, JH–H = 7.6 Hz, H
3), 8.26 (m, 1H, JH–H = 7.8 Hz,
1.0 Hz, H4), 8.99 (m, 1H, H6). 13C{1H} NMR (acetone-d6,
125.77 MHz, 300 K): 47.5 (s, CH2-py
b), 53.6 (d, 1JP–C = 17.6 Hz,
P–CH2), 73.1 (d,
3JP–C = 10.1 Hz, N–CH2–N), 125.7 (d,
4JP–C =
3.8 Hz, C5), 127.5 (d, 4JP–C = 3.8 Hz, C
3), 129.5 (d, 4JP–C =
3.8 Hz, C5′), 129.8 (s, C4′), 131.1 (s, C3′), 134.6 (d, 3JP–C = 6.3 Hz,
C6′), 136.3 (s, Cipso), 142.7 (d, 2JP–C = 3.8 Hz, C–Au), 144.2 (s,
C4), 151.4 (s, C6), 156.9 (s, Cipso). 31P{1H} NMR (acetone-d6,
202.45 MHz, 300 K): −16.6 (s, PTA), −144.2 (h, 1JP–F = 711 Hz,
PF6). ESI-MS (MeCN–MeOH), positive mode exact mass for
[C18H22N4O3PAuCl]
+ (557.09306): measured m/z 557.09246
[M − PF6]+. IR (νmax, cm−1): 2935, 1611, 1565, 1446, 1413, 1283,
1243, 823, 775, 737, 310, 227. Anal. Calc. for C18H22N4O3P2-
F6AuCl·CH2Cl2: C, 28.97, H, 3.07, N, 7.11%. Found: C, 28.96,
H, 2.02, N, 7.26%.
[(Au(pyb-H)(GluS)Cl] (3). A round-bottom flask was charged
with 1 (1 eq., 50 mg, 0.115 mmol), thio-β-D-glucose tetraacetate
(GluSH) (1 eq., 42 mg, 0.115 mmol) and Na2CO3 (2 eq., 24 mg,
0.230 mmol) in suspension in dichloromethane (5 mL). The
reaction was maintained at room temperature for around 1.5 h
(until the solution turned yellow). The solution was filtered
through Celite® and concentrated under reduced pressure.
Upon addition of pentane a yellow precipitate was formed that
was filtered oﬀ and dried under vacuum to give compound 3
as a 1 : 1 mixture of diastereomers (83.9 mg, 96% yield).
1H NMR (acetone-d6, 500.13 MHz, 298 K): 1.89/1.94 (2 s, 3H,
CH3), 1.95 (s, 3H, CH3), 1.98/1.99 (2 s, 3H, CH3), 2.07/2.09 (2 s,
3H, CH3), 3.74 (m, 1H, CH), 4.02/4.13 (2 dd, 1H, JH–H = 12.0 Hz,
2.0 Hz, CH2-sugar), 4.22/4.26 (2 dd, 1H, JH–H = 12.0 Hz, 5.5 Hz,
CH2-sugar), 4.33 (d, 1 H, JAB = 14.5 Hz, CHAHB-py
b), 4.52 (d, 1 H,
JAB = 14.5 Hz, CHAHB-py
b), 4.99–5.09 (m, 2H, 2 CH), 5.17–5.25
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(2 t, 1H, JH–H = 9.5 Hz, CH), 5.45/5.64 (2 d, 1H, JH–H = 9.5 Hz,
CH), 7.08–7.12 (2m, 1H, JH–H = 5.5 Hz, H
5′), 7.16–7.20 (m, 1H,
H4′), 7.29–7.31 (2 d, 1H, JH–H = 5.5 Hz, H
3′), 7.33/7.58 (2 d, 1H,
JH–H = 5.5 Hz, H
6′), 7.70–7.73 (m, 1H, H5), 7.98 (broad d, 1H,
JH–H = 8.0 Hz, H
3), 8.22 (m, 1H, JH–H = 8.0 Hz, H
4), 9.17/9.20 (2
d, 1H, JH–H = 5.5 Hz, H
6). 13C{1H} NMR (acetone-d6,
125.77 MHz, 300 K): 20.6–21.0 (CH3), 47.9 and 48.0 (CH2-py
b),
63.0 (CH2-sugar), 69.7/69.8, 73.0/73.3, 75.4, 76.2/76.4 and 83.0/
83.1 (CH-sugar), 125.3 (C5), 127.1 (C3), 128.7 (C4′/5′), 128.8
(C4′/5′), 129.9/130.0 (C3′), 131.9–133.1 (C6′), 134.0/134.1 (C–Au),
143.1/143.2 (C4), 144.5/144.6 (Cipso), 152.0/152.1 (C6), 156.9/
157.1 (Cipso), 169.8–170.9 (CvO). ESI-MS (DMSO-MeOH), posi-
tive mode exact mass for [C26H29NO9SAuClNa]
+ (786.08093):
measured m/z 786.07946 [M + Na]+. IR (νmax, cm
−1): 1743,
1612, 1569, 1435, 1367, 1219, 1029, 912, 753, 376, 295, 221.
Anal. Calc. for C26H29NO9SAuCl: C, 40.87, H, 3.83, N, 1.83,
S, 4.20%. Found: C, 40.58, H, 4.18, N, 1.85, S, 3.73%.
[Au(pyb-H)(GluS)2] (4). A round-bottom flask was charged
with 1 (1 eq., 50 mg, 0.115 mmol), thio-β-D-glucose tetraacetate
(2 eq., 84 mg, 0.230 mmol,) and Na2CO3 (5 eq., 61 mg,
0.575 mmol) in suspension in dichloromethane (10 mL). The
reaction mixture was maintained at room temperature over-
night until the solution turned yellow. The solution was fil-
tered through Celite® and concentrated under reduced
pressure. Upon addition of pentane a yellow precipitate was
formed which was filtered oﬀ and dried under vacuum to give
the analytical sample (93.5 mg, 74% yield). 1H NMR (acetone-
d6, 300 K, 500.13 MHz): 1.91 (s, 4H, CH3), 1.93–1.95 (m, 8H,
CH3), 2.00 (s, 6H, CH3), 2.09 (s, 3H, CH3), 2.11 (s, 3H, CH3),
3.24–3.28 (m, 0.7H, CH), 3.51–3.56 (m, 0.3 H, CH), 3.76–3.82
(m, 1.7H, CH), 4.02 (dd, 1H, JH–H = 8.0 Hz, 4.0 Hz, CH), 4.06
(m, 0.3H, CH), 4.12 (dd, 1H, JH–H = 8.0 Hz, 2.5 Hz, CH),
4.20–4.32 (m, 2.5H, CH-sugar + CHAHB-py
b), 4.43 (d, 1H, JAB =
14.5 Hz, CHAHB-py
b), 4.50 (d, 0.7H, JH–H = 9.5 Hz, CH), 4.79 (t,
0.7H, JH–H = 9.8 Hz, CHCH2), 4.93 (t, 0.7H, JH–H = 9.8 Hz,
CHCH2), 4.97–5.13 (m, 4H, CH), 5.18–5.24 (m, 1.7H, CH), 5.42
(d, 0.7H, JH–H = 10.5 Hz, CH), 7.09–7.15 (m, 2H, H-py
b),
7.30–7.33 (m, 1 H, H-pyb), 7.53 (dd, 0.3H, JH–H = 7.0 Hz, 1.5
Hz, H6′), 7.62 (dd, 0.7H, JH–H = 7.0 Hz, 1.5 Hz, H
6′), 7.67–7.72
(m, 1H, H-pyb), 7.96 (d, 1H, JH–H = 7.5 Hz, H-py
b), 8.19–8.24
(m, 1H, H-pyb), 9.39 (dd, 0.7H, JH–H = 6.0 Hz, 1.0 Hz, H
6), 9.45
(d, 0.3H, JH–H = 6.0 Hz, H
6). 13C{1H} NMR (acetone-d6, 300 K,
125.77 MHz): major isomer: 20.6, 20.7, 20.8, 21.0 and 21.5
(CH3), 48.8 (CH2-py
b), 62.7 and 62.8 (CH2-sugar), 69.4, 69.5,
72.8, 74.7, 75.6, 75.7, 75.9, 76.1, 82.4 and 83.6 (CH-sugar),
125.0, 127.1, 128.0, 128.6, 129.4 and 132.5 (CH-pyb), 135.4
(C-Au), 142.9 and 153.1 (CH-pyb), 154.8 and 157.7 (Cipso-pyb),
169.7, 169.8, 170.0, 170.1, 170.2, 170.2, 170.7 and 170.9
(CvO); minor isomer: 20.6, 20.7, 21.1 and 21.2 (CH3), 48.4
(CH2-py
b), 63.0, 63.2, 69.6, 70.0, 73.6, 75.0, 75.3, 76.4, 76.6,
83.8 and 84.8 (CH-sugar), 123.8, 125.4, 126.9, 127.8, 131.7 and
133.4 (CH-pyb), 134.5 (C–Au), 137.2 (CH-pyb), 150.4 (Cipso-pyb),
152.9 (CH-pyb), 157.9 (Cipso-pyb), 169.8, 169.9, 170.1 and 170.8
(CvO). (CH2Cl2/MeOH), positive mode exact mass for
[C40H48NO18S2AuNa]
+ (1114.18705): measured m/z 1114.18560
[M + Na]+. IR (νmax, cm
−1): 1740, 1614, 1569, 1437, 1367, 1218,
1029, 754, 375, 369, 212. Anal. Calc. for C40H48AuNO18S2·H2O:
C, 43.29, H, 4.54, N, 1.26, S, 5.78%. Found: C, 43.11, H, 4.72,
N, 1.30, S, 4.78%.
X-ray crystallography
Crystals of 2-PF6 were obtained by slow diﬀusion of diethyl
ether into a concentrated solution of 2-PF6 in acetone. Inten-
sity data were collected on a Bruker Kappa CCD APEX II at
115 K. The structure was solved by direct methods (SIR92)32
and refined with full-matrix least-squares methods based on
F2 (Shelx 97)33 with the aid of the Olex2 program.34 All non-
hydrogen atoms were refined with anisotropic thermal para-
meters. Hydrogen atoms were included in their calculated
positions and refined with a riding model. Crystallographic
data are reported in Table S1 (ESI†).
Cell viability assay
The human breast cancer cell line MCF7, the human lung
cancer cell line A549 and the human ovarian cancer cell line
A2780 were obtained from the European Centre of Cell Cul-
tures ECACC, Salisbury, UK. Human colon cancer cell lines
HCT116 p53+/+ and HCT116 p53−/− were a kind gift from
Dr Götz Hartleben (ERIBA, Groningen, NL), while non-tumoral
human embryonic kidney cells HEK-293T were kindly provided
by Dr Maria Pia Rigobello (CNR, Padova, Italy). Cells were cul-
tured in DMEM (Dulbecco’s modified Eagle medium) or RPMI
containing GlutaMax, supplemented with 10% FBS and 1%
penicillin/streptomycin (all from Invitrogen), at 37 °C under a
humidified atmosphere of 95% of air and 5% CO2 (Heraeus,
Germany).
For evaluation of growth inhibition, cells were seeded in
96-well plates (Costar, Integra Biosciences, Cambridge, MA) at
a concentration of 10 000 cells per well (A2780, MCF-7,
HEK-293T) or 6000 cells per well (HCT116, A549) and grown
for 24 h in complete medium. Solutions of the gold com-
pounds were prepared by diluting a freshly prepared stock
solution (10−2 M in DMSO) of the corresponding compound in
aqueous media (RPMI or DMEM for the A2780 or A549,
MCF-7, HCT116 p53+/+ and HEK-293T, respectively). Stability
in DMSO was checked by NMR, and the compounds resulted
to be stable over several hours. Cisplatin was purchased from
Sigma-Aldrich and stock solutions were prepared in water.
Afterwards, the intermediate dilutions of the compounds in
the cell culture medium were added to the wells (200 μL) to
obtain a final concentration ranging from 0 to 50 μM, and the
cells were incubated for 72 h. Afterwards, 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) was added
to the cells at a final concentration of 0.5 mg ml−1 and incu-
bated for 2 h, then the culture medium was removed and the
violet formazan (artificial chromogenic precipitate of the
reduction of tetrazolium salts by dehydrogenases and
reductases) dissolved in DMSO. The optical density of each
well (96-well plates) was quantified three times in quadrupli-
cates at 550 nm using a multi-well plate reader, and the per-
centage of surviving cells was calculated from the ratio of
absorbance of treated to untreated cells. The IC50 value was
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calculated as the concentration reducing the proliferation of
the cells by 50% and it is presented as a mean (±SE) of at least
three independent experiments.
PARP-1 activity determinations
PARP-1 activity was determined using Trevigen’s HT Universal
Colorimetric PARP assay. This assay measures the incorpor-
ation of biotinylated poly(ADP-ribose) onto histone proteins in
a 96 microtiter strip well format. Recombinant human PARP-1
(high specific activity, purified from E. coli containing recom-
binant plasmid harboring the human PARP gene, supplied
with the assay kit) was used as the enzyme source. 3-Amino-
benzamide (3-AB), provided in the kit, was used as the control
inhibitor. Two controls were always performed in parallel: a
positive activity control for PARP-1 without inhibitors, that pro-
vided the 100% activity reference point, and a negative control,
without PARP-1 to determine background absorbance. The
final reaction mixture (50 μL) was treated with TACS-Sapphire,
a horseradish peroxidase colorimetric substrate, and incubated
in the dark for 30 min. Absorbance was read at 630 nm after
30 min. The data correspond to the mean of at least three
experiments performed in triplicate ± SD.
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